Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EMBARQ-CSU1
NCT06445023Phase 3Active, not recruiting
- Sponsor
- Celldex Therapeutics
- Start
- Jul 2024
- Primary completion
- Oct 2026
- Modality
- Monoclonal Antibodies
- Countries
- 21
01
Overview
Phase 3, randomised, double-blind trial of barzolvolimab in chronic spontaneous urticaria (CSU) (4 arms), sponsored by Celldex Therapeutics. Primary endpoint: Urticaria Activity Score at 12 weeks. Started Jul 2024; status: active, not recruiting.
02
Drugs
barzolvolimab
03
Conditions
chronic spontaneous urticaria (CSU)
Beyond the preview
Go deeper on NCT06445023.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06445023.